John Renger - Oct 4, 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol
CERE
Transactions as of
Oct 4, 2022
Transactions value $
-$560,922
Form type
4
Date filed
10/6/2022, 04:59 PM
Previous filing
Aug 12, 2022
Next filing
Nov 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $35.1K +10K +370.49% $3.50* 12.7K Oct 4, 2022 Direct F1
transaction CERE Common Stock Options Exercise $154K +15K +117.76% $10.28 27.7K Oct 4, 2022 Direct F1
transaction CERE Common Stock Sale -$750K -25K -90.24% $30.00 2.7K Oct 4, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -10K -12.5% $0.00 70.1K Oct 4, 2022 Common Stock 10K $3.50 Direct F1, F2
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -15K -11.1% $0.00 120K Oct 4, 2022 Common Stock 15K $10.28 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
F2 25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.